Hua Medicine ("the Company," Hong Kong Stock Exchange stock code: 2552.HK) today announced that it will present research findings on dorzagliatin, its first-in-class glucokinase activator (GKA), at the 28th Annual Meeting of the Chinese Diabetes Society (CDS) of the Chinese Medical Association, via symposia, e-posters and written abstract presentations.
Hua Medicine (the "Company", HKEx: 2552) announced the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2026 (the "Reporting Period"), as well as the Company's business progress during the first half of the year and future outlook.
Hua Medicine ("the Company", HKEX Stock Code: 2552) announced today that dorzagliatin (trade name: MYHOMSIS®, 華領片®), the Company's first-in-class glucosekinase activator (GKA), has been dispensed its first prescription in Hong Kong.
ir@huamedicine.com
No.275 Ai Di Sheng Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203